GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aequus Pharmaceuticals Inc (FRA:AEQ) » Definitions » Gross-Profit-to-Asset %

Aequus Pharmaceuticals (FRA:AEQ) Gross-Profit-to-Asset % : 71.54% (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Aequus Pharmaceuticals Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Aequus Pharmaceuticals's annualized Gross Profit for the quarter that ended in Dec. 2024 was €0.40 Mil. Aequus Pharmaceuticals's average Total Assets over the quarter that ended in Dec. 2024 was €0.55 Mil. Therefore, Aequus Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 71.54%.


Aequus Pharmaceuticals Gross-Profit-to-Asset % Historical Data

The historical data trend for Aequus Pharmaceuticals's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aequus Pharmaceuticals Gross-Profit-to-Asset % Chart

Aequus Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 105.48 73.61 42.43 10.22 34.90

Aequus Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.87 12.94 28.61 31.87 71.54

Competitive Comparison of Aequus Pharmaceuticals's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Aequus Pharmaceuticals's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aequus Pharmaceuticals's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aequus Pharmaceuticals's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Aequus Pharmaceuticals's Gross-Profit-to-Asset % falls into.


;
;

Aequus Pharmaceuticals Gross-Profit-to-Asset % Calculation

Aequus Pharmaceuticals's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=0.223/( (0.742+0.536)/ 2 )
=0.223/0.639
=34.90 %

Aequus Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=0.396/( (0.571+0.536)/ 2 )
=0.396/0.5535
=71.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Aequus Pharmaceuticals Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Aequus Pharmaceuticals's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aequus Pharmaceuticals Business Description

Traded in Other Exchanges
Address
200 Granville Street, Suite 2820, Vancouver, BC, CAN, V6C 1S4
Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The Company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products, namely Tacrolimus IR and Vistitan.

Aequus Pharmaceuticals Headlines

No Headlines